跳至主要内容
临床试验/CTRI/2016/05/006916
CTRI/2016/05/006916招募中2 期

Study of efficacy and safety of neo adjuvant chemotherapy in patients with Stage 2 B and 3 NSCLC: A pilot study

investigator initiated study0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Pathological diagnosis of NSCLC
  • 2.Age 18 to 75 years
  • 3.ECOG PS 0-2
  • 4.Local disease T3 (with > 5cm contact with chest wall) or T4
  • 5.Mediastinal stage N0, N1 or non bulky N2 (defined as single station N2 station node <2 cms in size or multiple matted nodes but < 2cm at single N2 station) documented on PET scan and EBUS TBNA

排除标准

  • 1.ECOG PS >2
  • 2.Gross mediastinal structures invasion
  • 4.Immunocompromised
  • 5.Multiple comorbidities precluding possibilty of surgery
  • 6.Poor PFT (predicted post operative FEV1 < 800 cc not suitable for single lung anaesthesia)
  • 7.Pregnent and lactating females

研究者

发起方
investigator initiated study

相似试验

eoadjuvant chemotherapy in NSCLC | 临床试验